A novel monoclonal antibody , etaracizumab, previously known as MEDI523 or LM609, represents a notable advance in complement blocker development . It's uniquely designed to block the impact of factor H , a https://katrinaolmc257184.blognody.com/50854008/etaracizumab-medi523-lm609-a-deep-investigation